HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYNEndocrinology NetworkPractical CardiologyRheumatology Netowrk

Stephen Silberstein, MD: Migraine Therapies to Expect in 2019

SAP Partner | <b>Vickie and Jack Farber Institute for Neuroscience</b>

The Director of the Jefferson Headache Center spoke about migraine therapies that hold excitement and promise in the new year.

"As we move into the year 2019, what am I excited about? I think the small molecule CGRP antagonist will become available for both the acute and the preventive treatment of migraine."

The future of migraine treatment is bright. In the last 5—10 years, there’s been an introduction of new mechanism-based treatments: CGRPs. The CGRP inhibitors are the first drugs specifically approved for prevention of migraine in more than 50 years.

In 2018 alone, the FDA approved 3 CGRP inhibitors, erenumab (Aimovig, Amgen/Novartis), fremanezumab (Ajovy, Teva), and galcanezumab (Emgality, Eli Lilly). With the availability of new therapies, which provide clinicians a range of options, there are new possibilities for treatment on the horizon.

Stephen Silberstein, MD, Professor of Neurology, Thomas Jefferson University, and Director of the Jefferson Headache Center, spoke with NeurologyLive in an interview to discuss some of the therapies he believes to hold promise and excitement in 2019.